iRadimed Corp Reports 13% Revenue Growth in Q1 2026 Amid New Product Demand
iRadimed Corp (NASDAQ:IRMD) recorded a 13% revenue increase to $22 million in Q1 2026, driven by strong demand for its new products. The company is targeting a $50 million annual revenue run rate for pumps and anticipates a controlled growth trajectory moving forward.
Theia Market Signal Identification - AI Assisted
iRadimed Corp reported a revenue of $22 million for Q1 2026, marking a 13% increase year-over-year. Operating income improved by 33% to $7.2 million, largely due to effective cost management. The company projects Q2 2026 revenue between $20 million and $21 million, indicating a potential decline from Q1.
Challenges in ramping production for the new 3,870 MR IV pump system may limit revenue growth despite initial strong demand, with an effective tax rate of approximately 25% for the quarter. The company aims for a revenue run rate exceeding $100 million in 2026, influenced by increased orders for the four-channel systems.
Comments